Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 2Phase 1/2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Gynecologic 1Genitourinary 1CNS 1Breast 1

Conditions

Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Leukemia, Myeloid, Acute 7Recurrence 5Colonic Neoplasms 5Thyroid Neoplasms 4Thyroid Diseases 4Thyroid Cancer, Papillary 4Thoracic Neoplasms 4Respiratory Tract Neoplasms 4Respiratory Tract Diseases 4Neuroblastoma 4Neoplasms by Site 4Lung Neoplasms 4Lung Diseases 4Head and Neck Neoplasms 4Endocrine System Diseases 4Endocrine Gland Neoplasms 4Carcinoma, Bronchogenic 4Bronchial Neoplasms 4Breast Neoplasms 4Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Leukemia, Lymphocytic, Chronic, B-Cell 3Central Nervous System Neoplasms 3Carcinoma, Medullary 3Urinary Bladder Neoplasms 2Pancreatic Neoplasms 2

Interventions

sacituzumab govitecan 1cabozantinib 1Sorafenib 1Nivolumab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Has announcements × Carcinoma, Hepatocellular × Clear all
NCT01658878 2025-12-24

CheckMate040

Bristol-Myers Squibb

Phase 1/2 Completed
657 enrolled 57 charts 2 FDA
Gastrointestinal

Carcinoma, Hepatocellular

NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Gilead Sciences

Phase 1/2 Completed
515 enrolled 28 charts 1 FDA
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡